Vident Investment Advisory’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-111,365
| Closed | -$8.59M | – | 414 |
|
|
2023
Q2 | $8.59M | Sell |
111,365
-67,461
| -38% | -$5.38M | 0.3% | 107 |
|
|
2023
Q1 | $14.8M | Buy |
178,826
+97,875
| +121% | +$8.11M | 0.48% | 38 |
|
|
2022
Q4 | $6.95M | Sell |
80,951
-37,596
| -32% | -$2.98M | 0.26% | 116 |
|
|
2022
Q3 | $6.92M | Buy |
118,547
+4,363
| +4% | +$275K | 0.23% | 129 |
|
|
2022
Q2 | $7.06M | Sell |
114,184
-14,758
| -11% | -$914K | 0.21% | 117 |
|
|
2022
Q1 | $7.67M | Buy |
128,942
+42,292
| +49% | +$2.7M | 0.2% | 116 |
|
|
2021
Q4 | $6.29M | Sell |
86,650
-13,512
| -13% | -$931K | 0.16% | 142 |
|
|
2021
Q3 | $7M | Buy |
100,162
+16,963
| +20% | +$1.19M | 0.21% | 89 |
|
|
2021
Q2 | $5.73M | Buy |
83,199
+5,772
| +7% | +$385K | 0.17% | 107 |
|
|
2021
Q1 | $5M | Sell |
77,427
-4,388
| -5% | -$283K | 0.17% | 107 |
|
|
2020
Q4 | $4.77M | Buy |
81,815
+12,730
| +18% | +$768K | 0.19% | 86 |
|
|
2020
Q3 | $4.37M | Buy |
69,085
+17,337
| +34% | +$1.2M | 0.22% | 91 |
|
|
2020
Q2 | $3.98M | Buy |
51,748
+3,835
| +8% | +$294K | 0.21% | 89 |
|
|
2020
Q1 | $3.58M | Buy |
47,913
+2,068
| +5% | +$143K | 0.23% | 81 |
|
|
2019
Q4 | $2.98M | Buy |
45,845
+2,262
| +5% | +$147K | 0.18% | 110 |
|
|
2019
Q3 | $2.76M | Buy |
43,583
+1,389
| +3% | +$90.8K | 0.24% | 74 |
|
|
2019
Q2 | $2.85M | Sell |
42,194
-1,590
| -4% | -$105K | 0.23% | 73 |
|
|
2019
Q1 | $2.85M | Buy |
43,784
+5,914
| +16% | +$393K | 0.15% | 159 |
|
|
2018
Q4 | $2.37M | Sell |
37,870
-6,218
| -14% | -$435K | 0.13% | 190 |
|
|
2018
Q3 | $3.4M | Sell |
44,088
-43,421
| -50% | -$3.28M | 0.13% | 188 |
|
|
2018
Q2 | $6.2M | Buy |
87,509
+12,581
| +17% | +$888K | 0.25% | 61 |
|
|
2018
Q1 | $5.59M | Buy |
74,928
+6,128
| +9% | +$487K | 0.23% | 62 |
|
|
2017
Q4 | $4.93M | Buy |
68,800
+19,833
| +41% | +$1.51M | 0.22% | 72 |
|
|
2017
Q3 | $3.97M | Buy |
48,967
+12,202
| +33% | +$933K | 0.21% | 79 |
|
|
2017
Q2 | $2.6M | Buy |
36,765
+602
| +2% | +$40.1K | 0.22% | 149 |
|
|
2017
Q1 | $2.46M | Buy |
36,163
+8,140
| +29% | +$572K | 0.24% | 167 |
|
|
2016
Q4 | $2.01M | Buy |
28,023
+303
| +1% | +$22.5K | 0.24% | 220 |
|
|
2016
Q3 | $2.19M | Sell |
27,720
-2,691
| -9% | -$219K | 0.29% | 173 |
|
|
2016
Q2 | $2.54M | Sell |
30,411
-60,977
| -67% | -$5.41M | 0.36% | 89 |
|
|
2016
Q1 | $8.39K | Buy |
91,388
+57,651
| +171% | +$5.2M | 0.52% | 7 |
|
|
2015
Q4 | $3.41M | Buy |
33,737
+6,809
| +25% | +$709K | 0.43% | 18 |
|
|
2015
Q3 | $2.64M | Buy |
26,928
+26,544
| +6,913% | +$2.95M | 0.37% | 38 |
|
|
2015
Q2 | $45K | Buy |
+384
| New | +$42K | 0.01% | 790 |
|
Other funds holding GILD
Vident Investment Advisory's GILD Position: Q3 2023 in Review
Vident Investment Advisory sold out of Gilead Sciences (GILD) in Q3 2023, closing a stake of 111,365 shares — an estimated $8.59M sold.
Vident Investment Advisory first reported a position in GILD in Q2 2015 and held it in 33 quarters. The position peaked at $14.8M in Q1 2023. 1,681 funds tracked by Wall St. Rank hold GILD as of Q3 2023.
- Vident Investment Advisory reported no remaining Gilead Sciences position as of Q3 2023 after selling out during the quarter.
- Vident Investment Advisory sold 111,365 Gilead Sciences shares in Q3 2023, an estimated $8.59M.
- Vident Investment Advisory first reported a position in Gilead Sciences in Q2 2015 and held it in 33 quarters.
- Vident Investment Advisory's Gilead Sciences position peaked at $14.8M in Q1 2023.
- 1,681 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2023.
Based on Vident Investment Advisory's 13F filing for Q3 2023.